sacituzumab govitecan
gilead sciences
['tropics-02', '$gild']
physician comments at #asco22 press conf largely supportive of $gild tropics-02 data. "one in five chance of not progressing at one year is still huge from a clinical perspective," says dr meisel. would welcome this an another option for these advanced patients.
Pharma and biotech reporter, found a home at Evaluate Vantage.